 |
Diffusion Pharmaceuticals
charlottesville, charlottesville pharma, pharmaceuticals charlottesville, diffusionpharma, pharma, pharmaceutical, diffusion, biotechnology, biotech, biotech charlottesville, charlottesville biotech charlottesville pharma, pharma charlottesville, technology charlottesville, charlottesville technology, first in class, commercialize, proprietary, diligent, resourceful, efficient, novel action, new discovery, pioneer, small molecule, breakthrough, clinical stage, clinical research, well tolerated, safe, new understanding, treatment, hypoxia, oxygen deprived tissue, multiple indications, large market potential, diffusion of oxygen, unmet medical needs, focused, visionary, credible, pipeline, results driven, momentum, extraordinary concept, expert, expertise, therapeutic, phase 2, phase two, phase ii, cutting edge, peripheral vascular disease, primary brain tumor, trauma, stroke, congestive heart failure, heart attack, hemorrhage, hemorrhagic, hemorrhagic stroke, peripheral arterial disease, PAD, CHF, cancer, multiple organ failure, unstable angina, respiratory disease, TIA, thrombosis, clot, brain blood, brain oxygen, MI, injury, head injury, drug development, drug candidates, human trials, efficacy, progressing, medications, therapy, treatment, revolutionary, strategic, oncology, researchers, collaborators, physicians, proof of effect, trans sodiumcrosetinate
clinical-stage drug-development company, first-in-class drug candidates, trans sodium crocetinate, small-molecule, novel method of action, oxygen diffusion, hypoxic, cardiovascular, respiratory diseases, stroke, cancer, phase 2 proof-of-concept, privately held
pipeline of first-in-class small molecules, a novel method of action, oxygen, hypoxic, diffusion, oxygen, delivering oxygen, enhance, oxygen diffusion into hypoxic tissue, diffusion pharmaceuticals, cardiovascular disease, cancer, respiratory disorders, proprietary molecules, TSC, increases the rate of oxygen diffusion, increase the diffusion of oxygen into hypoxic cancerous tumor tissue
pharmaceuticals, biotechnology, virginia piedmont technology council's navigator award, technology community, drug-development services, world-wide pharmaceutical, biotechnology industries, virginia biotechnology association
inventor of the trans bipolar carotenoid family of molecules, trans bipolar carotenoid molecules, hemorrhagic shock, acute respiratory distress syndrome, ards
medical technology, investor relations, biotechnology company
clinical development,pharmacokinetics, trans sodium crocetinate, hemorrhagic shock, acute lung injury
cardiovascular medicine, proprietary molecules, drug development industry, clinical trials, regulatory filings, project management, data management of trials, multiple indications, oncology and infection disease, nonverbal communication, deception detection,technology, investment, intellectual property, pharmaceutical development, biotechnology
scientific advisory board, scientists, clinicians, clinical development,oncology, medicine, neurological surgery, johns hopkins medical school, brain tumors, cancer pain, medical oncology, neuro-oncology craniofacial surgery, brain tumors, trauma, pediatric neurosurgery, spinal cord injury, oxygen delivery to tissue, organ integrity, microcirculation, vascular biology, oxygen delivery to tissue, new class of pharmaceutical compounds, intellectual property, patent, us patent no. 6060511, entire family of related novel chemical structures, novel chemical synthesis processes critical for manufacturing synthetic TSC to cGMP quality, clinical-stage drug-development company, novel method of action, enhances oxygen diffusion, us patent no 7351844, bipolary tras cartenoid salts, first-in-class, drug-development company, first-in-class drugs, novel mechanism of action, enhances oxygen diffusion, clinical-stage drug development company, first-in-class drugs, noel mechanism of action, enhances oxygen diffusion, phase i safety trial, trans sodium crocetinate, drug discovery and development company, treatment of life-threatening diseases, a clinical-stage drug discovery, trans sodium crocetinate, novel mechanism of action, enhance the diffusion of oxygen into tissue, revolutionary approach, pioneering, revolutionary approach, medical technology, us patent no 7351844, bipolar trans carotenoid salts, clinical-sage drug-development company, novel method of action, enhances oxygen diffusion, first-in-class oxygen enhancing therapeutic, clinical stage, first-in-class drugs, clinical stage drug development, first-in-class drugs, noel mechanism of action, enhances oxygen diffusion, trans sodium crocetinate TSC, pioneering a revolutionary approach, treatment of life-threatening diseases, scientific advisory board SAB, clinical-stage drug discovery and development company, trans sodium crocetinate tsc, novel mechanism of action, enhance the diffusion of oxygen into tissue, office of naval research, life-threatening diseases, revolutionary approach to treat life-threatening diseases, phase I trials, revolutionary mechanism of action, treat life-threatening diseases, investigational new drug, drug discovery and development company, revolutionary mechanism of action, treat life-threatening diseases, trans sodium crocetinate tsc, private equity round, drug discovery and development company, revolutionary mechanism of action, treat life-threatening diseases, novel small-molecule therapeutic, brain tumor therapy, clinical trials program, trans sodium crocetinate, novel small-molecule therapeutics, treatment of oxygen deficiency in issues, early-stage pharmaceutical company, develops novel small-molecule therapeutics, treat hypoxia, BIO CEO and investor conference, office of navel research ONR, noel small-molecule drug, trans sodium crocetinate tsc, drug-development company, noel small-molecule drug, tans sodium crocetinate tsc, tech journal south, astec center, charlottesville virginia, diffusion pharmaceuticals', breakthrough technology, develop partnerships, joint development, out-license of drug candidates, pharmaceutical, biotech, innovative new product, cardiovascular, oncology, respiratory, emergency medicine/trauma, diffusion pharmaceuticals llc, private equity investments, office of naval research ONR, private equity, accredited investors, individual income in excess of 200000, joint income with their spouse in excess of 300000, diffusion pharmaceuticals subscription agreement, oxygen to hypoxic, tissue, cardiovascular diseases, peripheral arterial disease, heart attack, congestive heart failure, solid cancerous tumors, radiation therapy, stroke, respiratory disorders, hypoxia-related conditions, trans sodium crocetinate tsc, diffusion of oxygen to tissue, therapeutic effect, good bioavailability, intravenously, intramuscular injection, inhalation, orally, molecules, proprietary family of drugs, synthesized, novel treatment for tissue oxygen deprivation, tissue hypoxia, peripheral arterial disease, narrowing of blood vessels, intermittent claudication ic, oxygenation of muscle tissue, relieve the pain of pad, phase 2 clinical trial, diffusion-limited hypoxia, prevailing cause of hypoxia, tumors, non-responsiveness of cancerous tumors to radiation therapy, oxygen deficiency within the cells of the tumor, brain cancer, tsc improves oxygenation of the tumor, increasing survival, proof-of-concept clinical trial, patients with brain tumors, ischemic conditions caused by stroke, myocardial infarction, respiratory disease, cardiovascular disease, respiratory disease, wide range of conditions, asthma to emphysema, tsc improves oxygenation, blood loss, major cause of death on the battlefield, tsc acts as a resuscitation agent in severe blood loss, trauma, improving oxygenation, preventing tissue damage, increasing survival, phase 1 study of trans sodium crocetinate, double-blind, placebo-controlled, dose-escalation study, pharmacokinetics of a single intravenous bolus injection of TSC, TSC is well-tolerated, successful completion of the companys phase 1 study, milestone in the clinical development of tsc breakthrough technology, commercialization, clinical efficacy, tissue hypoxia, treatment of cancerous brain tumors in conjunction with radiation therapy, treatment of severe leg pain called intermittent claudication, peripheral arterial disease pad, life-threatening medical needs, potential billion dollar markets, non-responsiveness of many cancerous tumors to radiation therapy, oxygen deficiency within the tumor, promote enhanced oxygen diffusion into tissue, boost the response to radiation therapy, national cancer institute, the johns hopkins university, university of virginias department of neurosurgery, a proof-of-concept study, patients with brain tumors, clinical trials, tsc as a radiation sensitizer, brain tumors, stage II pad, intermittent claudication, heart attack, stroke, colorado prevention center, phase 2 clinical trials, trans cutaneous oxygen monitoring tcom, tissue oxygenation, pad, human proof-of-concept testing, measurable clinical end-points tumor shrinkage, prolonged survival in cancer patients, increased treadmill walking distance in pad patients, state-of-the-art oxygen-measuring techniques, enhance oxygenation to hypoxic tissue in humans, hypoxia, lack of oxygen, morbidity and mortality, oxygen-starved tissue, new treatment, life-threatening conditions, cardiovascular diseases, peripheral arterial disease, heart attack, congestive heart failure, solid cancerous tumors, radiation therapy, stroke, respiratory disorders, hypoxia-related conditions, trans sodium crocetinate, bioavailability, intravenously, intramuscular injection inhalation, orally, transdermally, pathway from the lungs to the cells, increasing oxygen, concentration within the blood, oxygen gas, artificial, hemoglobins, perflurocarbons, hypoxic tissue, oxygen toxicity, modified hemoglobins, small molecule, novel diffusion-enhancement approach, treating tissue hypoxia, oxygen deprivation, new paradigm, red blood cells, process of diffusion, diffusion, plasma membrane walls, tissue cells, plasma, major resistance to oxygen movement, hydrogen bonds, capable of forming four hydrogen bonds, hydrogen bonds, less dense liquid, enhanced hydrogen bonding, enhances, rate of diffusion, small molecules, oxygen and glucose, radiation oncology, ischemic stroke, hemorrhagic shock, acute lung injury, demonstrated therapeutically significant results, well-tolerated in humans, peer-reviewed articles, lack of oxygen to tissue, pharmacological treatment for hypoxia, deprived of oxygen, hypoxia, loss of consciousness, tissue necrosis, neurological incapacitation, acute hypoxia, oxygenated blood, embolus, blood clot, atherosclerosis, peripheral arterial disease, stroke, hypoxia, cancerous tumor tissue, critical/acute, chronic care, oncology, radio sensitizer, enhance radiation therapy, novel treatment for hypoxic conditions, tsc, cancerous, tumors, peripheral arterial disease, stroke, cardiovascular, respiratory disease, trauma, hemorrhagic shock, hypoxic cells, cancerous, tumors, radiation, therapy, oxygen, deficiency, narrowing of blood vessels, heart, and brain, ischemic conditions, stroke, myocardial infarction, respiratory disease, tissue, oxygenation, blood loss, death on the battlefield, respiratory disease, asthma to emphysema, tsc improves oxygenation of the tumor, increasing the effectiveness, peripheral arterial disease, oxygenation, resuscitation agent, severe blood loss, improving oxygenation, preventing tissue damage, increasing survival, in-vitro studies, improvement in survival, cardiovascular disease, ischemic penumbra, oxygen enhancement, hyperoxic animals, rat and mouse tumor models, radiation therapy, tsc, radiation therapy, tumor shrinkage, tumor control, in silico, enhanced diffusion, enhanced hydrogen bonding, increased tissue oxygen, trans-sodium crocetinate, hemorrhagic shock, oleic acid model, acute lung injury, effects on cytokines, blood pressure, increases oxygen delivery to brain, hemorrhagic shock, restores blood pressure, heart rate, plasma lactate, prolongs survival in lethal hypoxemia, a novel fluid resuscitation therapy, increasing oxygen consumption, survival, fluid resuscitation therapy, academic research organizations, the johns hopkins university, university of virginia, uniformed services university health sciences, new approaches to brain tumor therapy cns consortium, office of naval research, university collaborators, hypoxia, cellular level, cardiovascular, oncology, respiratory, emergency medicine, trauma, niche indications, matt hantzmon
Diffusionpharma.com ~
Site Info
Whois
Trace Route
RBL Check
|
Site Info
